We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NEUWAY Pharma, Cobra Biologics Collaborate
News

NEUWAY Pharma, Cobra Biologics Collaborate

NEUWAY Pharma, Cobra Biologics Collaborate
News

NEUWAY Pharma, Cobra Biologics Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NEUWAY Pharma, Cobra Biologics Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cobra Biologics Ltd and NEUWAY Pharma GmbH have announced the conclusion of a Service Agreement to develop a manufacturing process for the production of GMP grade material of Engineered Protein Capsules (EPCs) using SF9 cells and subsequent baculovirus infection.

The material will be used by NEUWAY for the conduct of GLP toxicity studies and initiation of clinical development in the treatment of Progressive Multifocal Leukoencephalopathy, a very severe neurodegenerative CNS disease. NEUWAY Pharma also uses its EPCs as a CNS Drug Delivery Platform by filling them with active drug substances.

Dr Heiko Manninga, Chief Scientific Officer (CSO) and Managing Director of NEUWAY Pharma commented: “The initiation of GMP development is an important step towards qualification of EPCs for clinical development. We are very happy that we have gained Cobra Biologics as partner for the GMP manufacturing of Engineered Protein Capsules.”

Peter Coleman, CEO Cobra Biologics commented: “We are very pleased to be manufacturing NEUWAY Pharma’s EPCs for what is a rare but serious disease, often resulting in severe disability or death. With Cobra’s 17 years of virus production experience we hope this is just the beginning of our collaboration.”

Advertisement